Institutions · Entity Annotation Prototype (beta)

3articles mentioning institutions

3institution mentions

1distinct institutions extracted

0%of mentions human-reviewed

Active filtersEntity: Johnson & Johnson ×

Johnson & Johnson

This institution is selected. Its supporting articles are shown below.

Johnson & Johnson3

Articles mentioning Johnson & Johnson

3 articles · page 1 of 1

P210 Guselkumab efficacy in moderate to severe ulcerative colitis by extent of disease and inflammatory burden in the QUASAR maintenance study

gutjnl · abstract · 2026-06-23 · 1 matching annotations

89.7%

Johnson & Johnson NCT04033445 Guselkumab GUS ulcerative colitis

…h GUS 200mg SC q4w compared with GUS 100mg SC q8w.Study support Johnson & Johnson.References Sachen KL, et al. Guselkumab binding to CD64+ IL-23–…

P217 Maintenance of endoscopic and histologic efficacy with guselkumab for ulcerative colitis at week 92 of the QUASAR long-term extension study

gutjnl · abstract · 2026-06-23 · 1 matching annotations

82.5%

Johnson & Johnson Guselkumab ulcerative colitis GUS GUS-treated

…ved at W92 of the LTE with both GUS dose regimens.Study Support Johnson & Johnson.References Rubin DT, et al. Guselkumab in patients with moderat…

70 Redefining superior vena cava isolation: integrated 3d mapping meets pulsed-field ablation-a safe and feasible approach with novel pfa catheters

heartjnl · abstract · 2025-10-14 · 1 matching annotations

80.4%

Boston Scientific Johnson & Johnson atrial fibrillation AF Superior vena cava isolation paroxysmal AF

… PFA catheters were used: a pentaspline catheter (FARAWAVE NAV, Boston Scientific, USA) and a variable-loop biphasic circular catheter (VARIPULSE…